Big Pharma's 3 Most Expensive Stocks

Before you go, we thought you'd like these...
Before you go close icon

The price-to-earnings ratio might be the most polarizing statistic in investing. Some investors call it a basic core tenet for judging stocks; others see it as a misguided and useless tool. Strong earnings or a big run-up in share price can skew the P/E ratio toward more expensive stocks, but how does this classic statistic measure up when viewing Big Pharma's priciest picks?

Using data compiled from stock screening site Finviz, let's check out the three most expensive stocks among major pharmaceutical developers. In the following video, Fool contributor Dan Carroll tells you what you need to know about these stocks -- and whether their outlooks are worth the pretty penny you'll pony up to buy them.

One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article Big Pharma's 3 Most Expensive Stocks originally appeared on

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading